Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients

Phase 4CompletedNCT00044720

Wyeth is now a wholly owned subsidiary of Pfizer484 enrolled

Overview

The incidence of efficacy failure at 12 months between two regimens.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

NONE

Enrollment

484

Conditions

Chronic Kidney Failure Graft vs Host Disease Kidney Transplantation

Interventions

RapamuneDRUG

Eligibility

Sex: ALLMin age: 13 Years

Medical Language ↔ Plain English

Inclusion Criteria * Age: 13 years or older, 40 kgs or more * End-stage renal disease * African-American/Black transplant recipient and/or repeat renal transplant recipient who lost a previous allograft Exclusion Criteria * Evidence of active infection * Evidence abnormal chest x-ray * Patients with HIV.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.